HealthCare Royalty ("HCRx") is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $7+ billion in over 110 biopharma products since inception and has offices in Boston, London, Miami, NY Metro Area and San Francisco. The HCRx team consists of 34 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants.

Our philosophy is simple - We are asset-focused investors seeking to identify compelling investment opportunities that will generate long-term value. We target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceuticals sectors.

Our investment platform is designed to serve as a long-term capital resource for our partners; flexible and directly aligned with their business models and objectives. Our team utilizes multiple investment approaches to help our partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCRx's senior professionals have completed more than 60 healthcare investments.